Full Answer
Should Medicare be allowed to negotiate drug prices?
According to Senator Wyden’s principles document, allowing Medicare to negotiate drug prices could address circumstances of market failure around drug prices, such as when there is inadequate or no competition or when drugs launch at high prices that may not be justified based on their clinical value.
Should HHS have the authority to negotiate drug prices?
Proponents of this approach believe that giving the HHS Secretary the authority to negotiate drug prices would provide the leverage needed to lower drug costs, particularly for high-priced drugs for which there are no competitors, where private plans may be less able to negotiate lower prices.
Does Medicare have the power to control drug prices?
Medicare, which insures more than 60 million beneficiaries, doesn't have that power, mostly because Congress stopped it from getting the best drug prices years ago. But that could change. The anti-consumer poison pill was embedded in a law ironically called the Medicare Modernization Act.
How much would drug pricing negotiation reduce federal spending and revenue?
As proposed in H.R. 3, drug pricing negotiation would reduce federal spending by $456 billion and increase revenues by $45 billion over 10 years. This would include:
What is the Medicare price negotiation act?
The bill would direct the secretary of the Department of Health and Human Services (HHS) to negotiate lower drug prices under the Medicare Part D plan.
How much less is Medicare Part D?
In a statement to Healthline, industry representatives said the current negotiation system has resulted in Medicare Part D recipients paying 35 percent less than manufacturers’ list prices for drugs. “The so-called Medicare Drug Price Negotiation Act of 2017 isn’t about negotiation at all.
How much money would Medicare save?
Congressional Democrats estimate that Medicare negotiations would save beneficiaries at least $15 billion a year if Part D programs paid the same prices as Medicaid and the Veterans Administration do for drugs. Patients for Affordable Drugs, a nonprofit consumer organization, strongly supports the bill.
Does Medicare negotiate with pharmaceutical companies?
A new bill in Congress would allow Medicare to negotiate with pharmaceutical companies on the price of drugs. Supporters say this would drastically lower costs. Officials in the Medicaid program do it. The people at the U.S. Department of Veterans Affairs do it as well. So why don’t the folks overseeing the Medicare program negotiate ...
Can HHS negotiate drug prices?
Right now, federal law prohibits the HHS secretary from negotiating directly with pharmaceutical companies over drug prices. That is done instead by private health plans. The prices they negotiate reach the pharmacy level.
Does Mosley's plan lower healthcare costs?
Mosley added that these lower prices would also lower overall healthcare costs for seniors. He said older adults getting proper medications would reduce illnesses and result in less medical care, especially for lower-income beneficiaries.
Is Medicare a part of the pharmaceutical industry?
In addition, Medicare is a large participant in the prescription drug industry. In 2015, the health program for seniors accounted for 29 percent of all national pharmaceutical retail spending. The bill in Congress would allow the HHS secretary to use this leverage to negotiate directly with pharmaceutical companies.
Why is the pharmaceutical industry opposed to government involvement in drug price negotiations?
The pharmaceutical industry continues to express strong opposition to government involvement in drug price negotiations based on concerns that it could lower revenue for drug companies, have a dampening effect on research and development, and limit access to new drugs.
What percentage of healthcare costs are prescription drugs?
Prescription drug costs are a major concern for consumers and a fiscal challenge for public and private payers, representing 10% of national health spending and nearly 20% of health benefit costs for large employers and Medicare. In response, lawmakers are considering a broad range of policy options, including one that would allow ...
What is Medicare Part D?
Under the Medicare Part D program, which covers retail prescription drugs, Medicare contracts with private plan sponsors to provide a prescription drug benefit and gives plan sponsors authority to negotiate drug prices with pharmaceutical companies. The law that established the Medicare Part D benefit, which covers retail prescription drugs, ...
How long does it take for the HHS to lower drug prices?
The executive order, which also endorsed other proposals to lower drug prices, such as inflation caps, called for HHS to develop more specific proposals to lower drug prices within 45 days of the order’s issue date. In Congress, proposals to authorize the federal government to negotiate drug prices for Medicare and other payers appear ...
What are the principles of price negotiation?
The principles call for a policy that establishes clear criteria for which drugs to include in price negotiation , gives the HHS Secretary the requisite tools to negotiate a “fair” price, and creates incentives for manufacturers to participate in the negotiation process.
What is the effect of H.R. 3 on Medicare?
In an October 2019 letter to Chairman Pallone, CBO provided a preliminary estimate of the effects of the drug price negotiation provisions of H.R. 3 on Medicare spending. In prior analyses of drug price negotiation, CBO has said that repealing the non-interference clause and allowing price negotiations between the Secretary and drug manufacturers would yield negligible savings, primarily because the Secretary would have insufficient leverage to secure price concessions. In its analysis of H.R 3, however, CBO indicates that the provision to levy an excise tax on drug companies that do not enter into negotiations or agree to the maximum fair price provides the Secretary with needed leverage to achieve lower drug prices and federal savings.
How much did the CBO increase in revenue?
CBO also estimated an increase in revenues of about $45 billion over 10 years resulting from lower drug prices available to employers, which would reduce premiums for employer-sponsored insurance, leading to higher compensation in the form of taxable wages.
Who would negotiate with drugmakers in Medicare?
Under H.R. 3, the Secretary of Health and Human Services (HHS) would be authorized to negotiate directly with drugmakers in the Medicare program for lower prices for up to 250 prescription drugs each year, including the 125 most costly drugs offered by Medicare Part D plans or sold anywhere in the commercial market.
How much would the drug pricing negotiation reduce federal spending?
As proposed in H.R. 3, drug pricing negotiation would reduce federal spending by $456 billion and increase revenues by $45 billion over 10 years. This would include: an increase in government revenue from employers using savings from reduced premiums to fund taxable wage increases for their workers.
How many drugs are eligible for negotiation?
Each year, the HHS secretary would select at least 50 drugs from among the up to 250 drugs eligible for negotiation. Drugs that are new to market may be eligible for negotiation if the wholesale acquisition cost, also called the list price, is equal to or greater than the U.S. median household income ($78,500 in 2020).
Does Medicare pay higher drug prices?
Medicare, which does not have the authority to negotiate rebates for Part D drugs, was found to pay higher net prices, on average, for top-selling brand-name drugs than ...
Is there a repeal of the non-interference clause?
Many policymakers and consumer advocates have called for a straight repeal of this noninterference clause. In 2019, the U.S. House of Representatives passed a bill, H.R. 3, which included a price negotiation mechanism. Recently this bill was reintroduced in Congress.
Can Medicare negotiate drug prices?
In a nutshell, it would allow the Medicare program to directly negotiate pharmaceutical prices with drugmakers. Negotiations could apply to either all Medicare-covered drugs or just the costliest ones.
Why is Part D money wasted?
For two reasons, a significant chunk of that money is wasted on overpayments to drug companies: When Part D began, millions of patients were shifted over from Medicaid, the state-federal program for low-income people that gets far lower drug prices than Medicare. Suddenly, the cost of providing drugs to the same people shot up.
Can Medicare negotiate with medicaid?
Congress barred Medicare from negotiating the way Medicaid and the Department of Veterans Affairs do with drug makers to get lower prices. Instead, lawmakers insisted the job be done by private insurance companies.”. This is a quote from a USA Today editorial and it highlights the absurdity of prohibiting Medicare from negotiating prescription ...
Is Medicare Part D barred from Medicare Part D?
Both Medicaid and the Department of Veteran Affairs negotiate for lower prices, but Medicare Part D, from it’s inception in 2006, is barred from doing this. This is a very different scenario than in other countries, like Canada and Europe, where all government health plans bargain with the drug companies to protect their citizens.
Why doesn't Medicare have the power to negotiate the best prices?
Medicare, which insures more than 60 million beneficiaries, doesn't have that power, mostly because Congress stopped it from getting the best drug prices years ago. But that could change.
What did the Medicare Negotiation and Competitive Licensing Act do?
Shutterstock. The recently introduced Medicare Negotiation and Competitive Licensing Act would put Medicare directly in charge of demanding the lowest drug prices.
What is the anti-consumer pill?
The anti-consumer poison pill was embedded in a law ironically called the Medicare Modernization Act. Among other things, it put corporate Pharmacy Benefit Managers (PBMs) in charge of acquiring drugs through Medicare's "Part D" plan.
Can pharma companies lock in profits?
Pharma companies can lock in some of the highest profits of any industry -- for years. Countries with national or single-payer healthcare, it should be noted, offer drugs to citizens at a fraction of what U.S. consumers pay.
The benefits of allowing Medicare to negotiate drug prices
At present, the federal law prohibits Medicare from negotiating drug prices directly with manufacturers. Consequently, drug companies can set prices as high as the market will bear, meaning the government has essentially no choice but to cover many medications at unfair prices.
Other reforms that would lower drug costs
In addition to reducing prices through Medicare negotiation, other reforms under consideration would reduce beneficiary costs at the pharmacy and lower health care premiums.
Conclusion
Congress has the opportunity to pass drug pricing legislation that would be life-changing for millions of older adults. More than 4 in 5 seniors think drug costs are unreasonable. Senators should take the overwhelmingly popular step of enabling the federal government to negotiate prices.
Methodology
This methodology section describes the authors’ approach to determining which drugs would be eligible for negotiation by HHS. The analysis was based on the most recent publicly available version of drug price negotiation legislation, a draft released by the Senate Finance Committee on December 11, 2021.